Mandate

Vinge has advised GeneraLife in connection with its acquisition of Livio Group

Vinge has advised GeneraLife, one of Europe's largest fertility clinic groups and owned by KKR, in connection with its acquisition of Livio Group.

Livio is the largest fertility clinics group in the Nordics, present with 9 clinics in Sweden, Norway and Iceland. The acquisition also encompasses the Livio's own gamete bank, Livio Egg and Sperm Bank, with a sales hub in Denmark.

Vinge's team consisted of responsible partner Matthias Pannier and associates, Samra Baytar, Stina Bengtsson, Olivia Belding, Elias Bohlin (M&A), Trine Osen Bergqvist, Johan Wahlbom, Jakob Jeanrond, Victoria Fredén, Alva Chambert (Antitrust), Christoffer Nordin, Mika Jordan (Regulatory & Agreements), Rebecka Målquist (IP), Frida Ställborn, Karolina Cohrs (Real Estate), Calle Tengwall Pagels (Banking & Finance), Gustav Lindgren (Employment), Karolina Fuhrman (IT & GDPR) and Jessica Henning (Project Assistance).

Related

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Nordea and SEB enters into a SEK 2,000,000,000 credit facility agreement

On 22 April 2026, Nordea and SEB entered into a credit facility agreement in the aggregate amount of SEK 2,000,000,000 (with an accordion option for an additional SEK 400,000,000) with Humble Group AB (publ).
April 27, 2026

Vinge has advised Northmill in connection with its inaugural issuance of primary capital instruments (AT1)

Vinge has advised Northmill Group AB in connection with its issuance of SEK 275 million primary capital instruments (so called “AT1 bonds”) with a floating rate interest of 3-month STIBOR + 690 basis points. The AT1 bonds are perpetual with a first call option after five years and are intended to be admitted to trading on Nasdaq Transfer Market and, subsequently, on Nasdaq Stockholm.
April 27, 2026